Improving symptom control in early Parkinson-s disease

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 6, 2009, Pages 393-400

  Isaacson, Stuart H ^a   Hauser, Robert A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

COMT inhibitor; dopamine agonist; levodopa; MAO inhibitor; Parkinson s disease; therapy

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CREATININE CLEARANCE; DAYTIME SOMNOLENCE; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; DYSKINESIA; FIBROSIS; FOOT EDEMA; HALLUCINATION; HUMAN; HYPOTENSION; IMPULSE CONTROL DISORDER; INSOMNIA; LIVEDO RETICULARIS; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; ORTHOSIS; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; STIMULATION; VALVULAR HEART DISEASE;

EID: 77953425596     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609339383     Document Type: Review

References (65)

1. Abbott, R.D., Petrovitch, H., White, L.R., Masaki, K.H., Tanner, C.M., Curb, J.D. et al. (2001) Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57: 456-462.
2. Adler, C.H., Sethi, K.D., Hauser, R.A., Davis, T.L., Hammerstad, J.P., Bertoni, J. et al. (1997) Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49: 393-399.
3. Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F. et al. (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A National Multicenter Parallel-Group Randomized Study. J Neurol 253: 601-607.
4. Berg, D. ( 2008) Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis 5: 133-136.
5. Birkmayer, W. and Hornykiewicz, O. ( 2001) The effect of L-3,4-dihydroxyphenylalanine (= Dopa) on akinesia in Parkinsonism. 1961. Wien Klin Wochenschr 113: 851-854.
6. Bodis-Wollner, I., Yahr, M.D. and Mylin, L.H. ( 1984) Nonmotor functions of the basal ganglia. Adv Neurol 40: 289-298.
7. Boeve, B.F., Dickson, D.W., Olson, E.J., Shepard, J.W., Silber, M.H., Ferman, T.J. et al. (2007) Insights into rem sleep behavior disorder pathophysiology in brainstem-predominant lewy body disease. Sleep Med 8: 60-64.
8. Braak, H. and Del Tredici, K. ( 2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70: 1916-1925.
9. Carlsson, A. ( 1959) Detection and assay of dopamine. Pharmacol Rev 11: 300-304.
10. Carlsson, A. ( 1964) Evidence for a role of dopamine in extrapyramidal functions. Acta Neuroveg (Wien) 26: 484-493.
11. Chaudhuri, K.R., Healy, D.G. and Schapira, A.H. ( 2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245.
12. Constantinescu, R., Romer, M., Mcdermott, M.P., Kamp, C. and Kieburtz, K. ( 2007) Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 22: 1317-1319.
13. Cotzias, G.C., van Woert, M.H. and Schiffer, L.M. ( 1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374-379.
14. Doshay, L.J., Constable, K. and Zier, A. ( 1954) Five year follow-up of treatment with trihexyphenidyl (artane); outcome in four hundred eleven cases of paralysis agitans. J Am Med Assoc 154: 1334-1336.
15. Fahn, S. and Isgreen, W.P. ( 1975) Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 25: 695-700.
16. Friedman, J.H., Brown, R.G., Comella, C., Garber, C.E., Krupp, L.B., Lou, J.S. et al. (2007) Fatigue in Parkinson's disease: a review. Mov Disord 22: 297-308.
17. Goldstein, M., Battista, A.F. and Miyamoto, T. ( 1975) Modification of involuntary movements by centrally acting drugs. Adv Neurol 9: 299-305.
18. Grandas, F., Galiano, M.L. and Tabernero, C. ( 1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246: 1127-1133.
19. Grosset, D., Taurah, L., Burn, D.J., Macmahon, D., Forbes, A., Turner, K. et al. (2007) A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78: 465-469.
20. Grosset, D.G. and Schapira, A.H. ( 2008) Timing the initiation of treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 79: 615.
21. Hauser, R.A., Lew, M.F., Hurtig, H.I., Ondo, W.G., Wojcieszek, J. and Fitzer-Attas, C.J. (2009 a) Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24: 564-573.
22. Hauser, R.A., Mcdermott, M.P. and Messing, S. ( 2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63: 1756-1760.
23. Hauser, R.A., Panisset, M., Abbruzzese, G., Mancione, L., Dronamraju, N. and Kakarieka, A. (2009 a) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa / carbidopa in early Parkinson's disease. Mov Disord 24: 541-550.
24. Hauser, R.A., Rascol, O., Korczyn, A.D., Jon Stoessl, A., Watts, R.L., Poewe, W. et al. (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22: 2409-2417.
25. Hillen, M.E. and Sage, J.I. ( 1996) Nonmotor fluctuations in patients with Parkinson's disease. Neurology 47: 1180-1183.
26. Hoehn, M.M. and Yahr, M.D. ( 1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
27. Hornykiewicz, O. ( 1962) Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man. Dtsch Med Wochenschr 87: 1807-1810.
28. Isaacson, S.H., Ailincai, M.L. and Kreitzman, D.L. ( 2008a) Effect of rotigotine on premotor and nonmotor symptoms in Parkinson's disease. Mov Disord 23: S334.
29. Isaacson, S.H., Ailincai, M.L. and Kreitzman, D.L. ( 2008b) Effect of rotigotine in the elderly with Parkinson's disease. Mov Disord 23: S217-S218
30. Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A. and Lees, A.J. ( 2008) Fourteen-year final report of the randomized Pdrg-Uk trial comparing three initial treatments in Pd. Neurology 71: 474-480.
31. Kostic, V., Przedborski, S., Flaster, E. and Sternic, N. ( 1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41: 202-205.
32. Kumar, N., van Gerpen, J.A., Bower, J.H. and Ahlskog, J.E. ( 2005) Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 20: 342-344.
33. Langston, J.W. ( 2006) The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596.
34. Lees, A.J., Shaw, K.M., Kohout, L.J., Stern, G.M., Elsworth, J.D., Sandler, M. et al. (1977) Deprenyl in Parkinson's disease. Lancet 2: 791-795.
35. Lemke, M.R., Brecht, H.M., Koester, J., Kraus, P.H. and Reichmann, H. ( 2005) Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 17: 214-220.
36. Lieberman, A., Kupersmith, M., Estey, E. and Goldstein, M. ( 1976) Treatment of Parkinson's disease with bromocriptine. N Engl J Med 295: 1400-1404.
37. Mehta, S.H., Morgan, J.C. and Sethi, K.D. ( 2008) Neuroimaging and transcranial ultrasonography in Parkinson's disease. Curr Neurol Neurosci Rep 8: 297-303.
38. Minguez-Castellanos, A., Chamorro, C.E., Escamilla-Sevilla, F., Ortega-Moreno, A., Rebollo, A.C., Gomez-Rio, M. et al. (2007) Do alpha-synuclein aggregates in autonomic plexuses predate lewy body disorders?: a cohort study. Neurology 68: 2012-2018.
39. Miyamoto, T., Miyamoto, M., Suzuki, K., Nishibayashi, M., Iwanami, M. and Hirata, K. ( 2008) 123i-Mibg cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic rem sleep behavior disorder. Sleep 31: 717-723.
40. Olanow, C.W., Rascol, O. for the ADAGIO Investigators (2008) ADAGIO: a prospective, double-blind, delayedstart study to examine the potential disease-modifying effect of rasagiline in early Parkinson's disease. Mov Disord 23: S194.
41. Pahwa, R., Stacy, M.A., Factor, S.A., Lyons, K.E., Stocchi, F., Hersh, B.P. et al. (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68: 1108-1115.
42. Palhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-Ikola, O. and Palm, R. ( 2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200-1206.
43. Palhagen, S., Heinonen, E.H., Hagglund, J., Kaugesaar, T., Kontants, H., Maki-Ikola, O. et al. (1998) Selegiline delays the onset of disability in de novo Parkinsonian patients. Swedish Parkinson Study Group. Neurology 51: 520-525.
44. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371.
45. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183.
46. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29-36.
47. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Jama 284: 1931-1938.
48. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59: 1937-1943.
49. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561-566.
50. Pogarell, O., Gasser, T., van Hilten, J.J., Spieker, S., Pollentier, S., Meier, D. et al. (2002) Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72: 713-720.
51. Rascol, O., Brooks, D.J., Korczyn, A.D., de Deyn, P.P., Clarke, C.E. and Lang, A.E. ( 2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N Engl J Med 342: 1484-1491.
52. Rascol, O., Brooks, D.J., Korczyn, A.D., de Deyn, P.P., Clarke, C.E., Lang, A.E. et al. (2006) Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21: 1844-1850.
53. Rektorova, I., Balaz, M., Svatova, J., Zarubova, K., Honig, I., Dostal, V. et al. (2008) Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 31: 261-266.
54. Rektorova, I., Rektor, I., Bares, M., Dostal, V., Ehler, E., Fanfrdlova, Z. et al. (2003) Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10: 399-406.
55. Schrag, A. and Quinn, N. ( 2000) Dyskinesias and motor fluctuations in Parkinson's disease. a community-based study. Brain 123(Pt 11): 2297-2305.
56. Schwartz, A.M., Olanow, C.W. and Spencer, A. ( 1973) A double-blind controlled study of Mk-486 in Parkinson's disease. Trans Am Neurol Assoc 98: 301-303.
57. Schwarzschild, M.A., Schwid, S.R., Marek, K., Watts, A., Lang, A.E., Oakes, D. et al. (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65: 716-723.
58. Shannon, K.M., Bennett Jr, J.P. and Friedman, J.H. ( 1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. the pramipexole study group. Neurology 49: 724-728.
59. Stiasny-Kolster, K., Doerr, Y., Moller, J.C., Hoffken, H., Behr, T.M., Oertel, W.H. et al. (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128: 126-137.
60. Stocchi, F., Hersh, B.P., Scott, B.L., Nausieda, P.A. and Giorgi, L. ( 2008) Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24: 2883-2895.
61. Watts, R.L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B. and Rao, J. ( 2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68: 272-276.
62. Weiner, W.J. and Reich, S.G. ( 2008) Agonist or levodopa for Parkinson disease?: Ultimately, it doesn't matter; neither is good enough. Neurology 71: 470-471.
63. Witjas, T., Kaphan, E., Azulay, J.P., Blin, O., Ceccaldi, M., Pouget, J. et al. (2002) Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology 59: 408-413.
64. Youdim, M.B., Gross, A. and Finberg, J.P. ( 2001) Rasagiline [N-propargyl-1r(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506.
65. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., Pezzoli. and G. ( 2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46.